Back to News
Market Impact: 0.55
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Source: reuters.com
Healthcare & BiotechCorporate Guidance & OutlookCompany Fundamentals
Novartis' late-stage trial of experimental del-desiran for a rare muscular dystrophy missed its goal last month, despite the CEO previously forecasting $5 billion in annual peak sales. Novartis shares fell 11%, erasing $30 billion in market value.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.55
Ticker Sentiment
NVS-0.80
More News
- Bayer’s CEO cut managers by 70%. Now comes the hard part
- AI companies run virtual drug trials, aim to improve success of human studies
- Former world No. 1 Jon Rahm's lawyer tells court Spaniard is done with LIV Golf after three seasons
- Anthropic will be 'most ridiculous IPO' of year, analyst says
- Levi Strauss hikes profit guidance after tariff refunds, but its sales outlook is less optimistic
- Samsung Q3 profit surges to record high, but misses lofty expectations
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Choosing an AI Copilot for Equity Research
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience